| Not Yet Recruiting | Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors Solid Tumor Malignancies, Malignant Mesothelioma (MM) | Phase 1 / Phase 2 | 2026-01-01 |
| Not Yet Recruiting | Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate C Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | 2025-08-01 |
| Not Yet Recruiting | Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer mCRPC | Phase 1 / Phase 2 | 2025-08-01 |
| Not Yet Recruiting | A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Re NSCLC | Phase 2 | 2025-02-20 |
| Completed | Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Hea NSCLC | Phase 1 | 2024-03-12 |
| Recruiting | A Study of TYK-00540 in Adult Patients With Solid Tumors Locally Advanced or Metastatic Solid Tumors | Phase 1 | 2024-01-02 |
| Recruiting | Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors HR-positive, HER2-negative Advanced Breast Cancer | Phase 1 / Phase 2 | 2024-01-02 |
| Recruiting | A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors Solid Tumor, Adult | Phase 1 | 2023-08-17 |
| Recruiting | TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases NSCLC, EGFR Activating Mutation, Brain Metastases | Phase 2 | 2023-08-17 |
| Completed | [14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects Healthy Volunteers | Phase 1 | 2023-06-19 |
| Unknown | A Study of TY-1091 in Patients With Advanced Solid Tumors RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer | Phase 1 / Phase 2 | 2023-04-24 |
| Unknown | A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | 2023-04-20 |
| Recruiting | Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) NSCLC, EGFR Activating Mutation | Phase 3 | 2022-06-08 |
| Completed | Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation NSCLC, EGFR Activating Mutation, Brain Metastases | Phase 2 | 2022-04-02 |
| Completed | A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers Healthy Volunteers | Phase 1 | 2021-04-30 |
| Unknown | A Study of TY-302 in Patients With Advanced Solid Tumors Breast Cancer, Solid Tumor | Phase 1 | 2020-12-07 |
| Completed | A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation NSCLC | Phase 1 | 2020-05-07 |